Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.

E Malden, Deborah; Hong, Vennis; J Lewin, Bruno; K Ackerson, Bradley; Lipsitch, Marc; A Lewnard, Joseph; Y Tartof, Sara

doi:10.15585/mmwr.mm7125e2

Public

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.

Shared by NobleBlocks on Jun 24, 2022 • 12:00 AM UTC

Authors:

Deborah E Malden

Vennis Hong

Bruno J Lewin

Abstract

Nirmatrelvir/ritonavir (Paxlovid) is a combination protease inhibitor that blocks replication of SARS-CoV-2 (the virus that causes COVID-19) and has been shown to reduce the risk for hospitalization and death among patients with mild to moderate COVID-19 who are at risk for progression to severe dis...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!